Pub. Date : 2006 Jun
PMID : 16789993
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 2 | OBJECTIVE: To clarify the effect of genetic polymorphism of CYP2C19 on pharmacokinetics of phenytoin and phenobarbital using a Non-linear Mixed Effects Modelling analysis in Japanese epileptic patients. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 3 | The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 4 | The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 5 | The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 6 | The total body clearance of phenobarbital decreased by 19.3% in patients with CYP2C19*1/*3 or the poor metabolizers of CYP2C19 compared with patients with normal CYP2C19 or with CYP2C19*1/*2. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 7 | CONCLUSION: These findings indicated that the genetic polymorphisms of CYP2C19 contribute to the pharmacokinetic variability of phenytoin and phenobarbital, the poor metabolizers of CYP2C19, which are relatively common in Asian groups. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |
| 8 | CONCLUSION: These findings indicated that the genetic polymorphisms of CYP2C19 contribute to the pharmacokinetic variability of phenytoin and phenobarbital, the poor metabolizers of CYP2C19, which are relatively common in Asian groups. | Phenobarbital | cytochrome P450 family 2 subfamily C member 19 | Homo sapiens |